LAFAYETTE, La., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced that it will host its third quarter 2024 earnings conference call on Thursday, November 7, 2024, at 12:00 p.m. EST.
Interested parties may participate in the call by dialing:
877-407-6176 (US Toll-Free)
+1 201-689-8451 (International)
Following the live call, a replay will be available in the Investor Relations section of the Company’s website at www.viemed.com.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. Visit our website at www.viemed.com.
For further information, please contact:
Glen Akselrod
Bristol Capital
905-326-1888
This email address is being protected from spambots. You need JavaScript enabled to view it.
Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.87 |
| Daily Change: | -0.04 -0.58 |
| Daily Volume: | 110,099 |
| Market Cap: | US$261.200M |
November 05, 2025 October 14, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
